Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity.

The company’s lead product candidate is beloranib, a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome, or PWS, craniopharyngioma-associated obesity, and severe obesity in the general population. Beloranib acts through potent inhibition of MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism.

Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors, which may be developed for the treatment of severe obesity in the general population.

$ 6.98 +0.15 (2.20%)
Day High: 7.11
Day Low:  6.63
Volume:    498,731
4:00 PM ET on
May 27, 2016

Delayed ~20 min., by eSignal.